EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenue was $221,000 compared with Nil a year ago. Loss from operations was $14,042,000 against $13,929,000 a year ago. Net loss was $13,987,000 against $13,935,000 a year ago. Basic and diluted loss per share was $0.59 against $1.28 a year ago.

For the nine months, the company reported revenue was $291,000 compared with Nil a year ago. Loss from operations was $36,272,000 against $29,100,000 a year ago. Net loss was $36,794,000 against $31,445,000 a year ago. Basic and diluted loss per share was $1.66 against $8.15 a year ago.